Please provide your email address to receive an email when new articles are posted on . Patients with cancer and overweight or obesity had better outcomes with immune checkpoint inhibitors than ...

Investigators sought to determine whether weight-based dosing of pembrolizumab could produce outcomes similar to standard fixed dosing for patients with NSCLC.

Overweight cancer patients receiving immunotherapy treatments live more than twice as long as lighter patients, but only when dosing is weight-based, according to a study by cancer researchers at UT ...

Patients with hepatitis C treated with combination therapy of pegylated interferon and ribavirin had better outcomes when taking a weight-based dosage of ribavirin compared to a flat dosage. This ...

The FDA recently approved the supplemental biologics license application for teclistamab (Tecvayli; Johnson & Johnson) to treat relapsed/refractory multiple myeloma on a biweekly dosing schedule.

Current GLP-1 standards of care focus on once-weekly dosing, with doctor-recommended, supervised titration depending on ...

We conducted a retrospective cohort study of 414 patients with advanced NSCLC treated with pembrolizumab at a single center between 2016 and 2021. Patients received either fixed-dose or weight-based ...

(BOSTON, Oct. 29, 2004) – Twice as many African-American patients infected with the most difficult-to-treat form of chronic hepatitis C successfully cleared the virus when given a weight-based dose of ...